K Dane Wittrup

List of Publications by Year
in descending order

191 papers	16,701 citations	14655 66 h-index	17592 121 g-index
195 all docs	195 docs citations	195 times ranked	15982 citing authors

#	Article	IF	Citations
1	Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ TÂcell immunity. Immunity, 2022, 55, 308-323.e9.	14.3	126
2	Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity. Nature Biomedical Engineering, 2022, 6, 129-143.	22.5	56
3	Maximizing response to intratumoral immunotherapy in mice by tuning local retention. Nature Communications, 2022, 13, 109.	12.8	45
4	Coâ€Anchoring of Engineered Immunogen and Immunostimulatory Cytokines to Alum Promotes Enhancedâ€Humoral Immunity. Advanced Therapeutics, 2022, 5, .	3.2	3
5	Yeast Surface Display for Protein Engineering: Library Generation, Screening, and Affinity Maturation. Methods in Molecular Biology, 2022, 2491, 29-62.	0.9	3
6	Intratumorally anchored cytokine therapy. Expert Opinion on Drug Delivery, 2022, 19, 725-732.	5.0	11
7	High-throughput phenotypic screen and transcriptional analysis identify new compounds and targets for macrophage reprogramming. Nature Communications, 2021, 12, 773.	12.8	62
8	Immunotherapy-induced antibodies to endogenous retroviral envelope glycoprotein confer tumor protection in mice. PLoS ONE, 2021, 16, e0248903.	2.5	6
9	Lack of CD8 ⁺ T cell effector differentiation during priming mediates checkpoint blockade resistance in nonâ€“small cell lung cancer. Science Immunology, 2021, 6, eabi8800.	11.9	58
10	Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity. Nature Cancer, 2020, 1, 882-893.	13.2	113
11	Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA. Molecular Cancer Therapeutics, 2020, 19, 2575-2584.	4.1	7
12	Pharmacokinetic tuning of proteinâ€“antigen fusions enhances the immunogenicity of T-cell vaccines. Nature Biomedical Engineering, 2020, 4, 636-648.	22.5	44
13	Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy. Science Translational Medicine, 2019, 11, .	12.4	141
14	Connecting the sequence dots: shedding light on the genesis of antibodies reported to be designed in silico. MAbs, 2019, 11, 803-808.	5.2	6
15	Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology, 2019, 9, 330.	2.8	12
16	Order of administration of combination cytokine therapies can decouple toxicity from efficacy in syngeneic mouse tumor models. OncoImmunology, 2019, 8, e1558678.	4.6	10
17	What, Why, Where, and When: Bringing Timing to Immuno-Oncology. Trends in Immunology, 2019, 40, 12-21.	6.8	50
18	Detection of amyloid Î² oligomers toward early diagnosis of Alzheimer's disease. Analytical Biochemistry, 2019, 566, 40-45.	2.4	25

#	Article	IF	Citations
19	Enhanced CARâ€“T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science, 2019, 365, 162-168.	12.6	282
20	Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis. Nature Communications, 2018, 9, 1461.	12.8	25
21	Artificial Anti-Tumor Opsonizing Proteins with Fibronectin Scaffolds Engineered for Specificity to Each of the Murine FcÎ³R Types. Journal of Molecular Biology, 2018, 430, 1786-1798.	4.2	10
22	Reduction of Nonspecificity Motifs in Synthetic Antibody Libraries. Journal of Molecular Biology, 2018, 430, 119-130.	4.2	44
23	CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. Blood, 2018, 131, 611-620.	1.4	49
24	A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling. Molecular Cancer Therapeutics, 2018, 17, 1773-1780.	4.1	8
25	Biophysical properties of the clinical-stage antibody landscape. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 944-949.	7.1	433
26	Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses. Journal of Experimental Medicine, 2017, 214, 1679-1690.	8.5	41
27	Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients. MAbs, 2017, 9, 257-268.	5.2	19
28	Nonspecificity in a nonimmune human scFv repertoire. MAbs, 2017, 9, 1029-1035.	5.2	24
29	Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer. Journal of Nuclear Medicine, 2017, 58, 1735-1742.	5.0	36
30	Chaperone proteins as single component reagents to assess antibody nonspecificity. MAbs, 2017, 9, 1036-1040.	5.2	26
31	An engineered protein antagonist of K-Ras/B-Raf interaction. Scientific Reports, 2017, 7, 5831.	3.3	55
32	Antitumor Antibodies Can Drive Therapeutic T Cell Responses. Trends in Cancer, 2017, 3, 615-620.	7.4	29
33	Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs. Journal of Molecular Biology, 2017, 429, 2528-2541.	4.2	13
34	Cytosolic delivery of siRNA by ultra-high affinity dsRNA binding proteins. Nucleic Acids Research, 2017, 45, 7602-7614.	14.5	11
35	Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors. Journal of Clinical Investigation, 2017, 127, 2176-2191.	8.2	241
36	Temporally Programmed CD8Î± + DC Activation Enhances Combination Cancer Immunotherapy. Cell Reports, 2016, 17, 2503-2511.	6.4	37

#	Article	IF	Citations
37	Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). AAPS Journal, 2016, 18, 861-875.	4.4	37
38	Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers. Cancer Research, 2016, 76, 6669-6679.	0.9	25
39	Target-independent variable region mediated effects on antibody clearance can be FcRn independent. MAbs, 2016, 8, 1269-1275.	5.2	34
40	Strong Enrichment of Aromatic Residues in Binding Sites from a Charge-neutralized Hyperthermostable Sso7d Scaffold Library. Journal of Biological Chemistry, 2016, 291, 22496-22508.	3.4	42
41	Design Principles for SuCESsFul Biosensors: Specific Fluorophore/Analyte Binding and Minimization of Fluorophore/Scaffold Interactions. Journal of Molecular Biology, 2016, 428, 4228-4241.	4.2	11
42	Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nature Medicine, 2016, 22, 1402-1410.	30.7	437
43	Generation of Fluorogen-Activating Designed Ankyrin Repeat Proteins (FADAs) as Versatile Sensor Tools. Journal of Molecular Biology, 2016, 428, 1272-1289.	4.2	22
44	Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 925-937.	6.4	38
45	Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. AAPS Journal, 2016, 18, 635-646.	4.4	60
46	A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin. Journal of Pharmaceutical Sciences, 2015, 104, 4409-4416.	3.3	13
47	Molecular Magnetic Resonance Imaging of Tumor Response to Therapy. Scientific Reports, 2015, 5, 14759.	3.3	43
48	Manipulating the Selection Forces during Affinity Maturation to Generate Cross-Reactive HIV Antibodies. Cell, 2015, 160, 785-797.	28.9	173
49	Five birds, one stone: Neutralization of Î±-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. MAbs, 2015, 7, 243-254.	5.2	125
50	High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. MAbs, 2015, 7, 770-777.	5.2	76
51	Immunotherapy: The Path to Win the War on Cancer?. Cell, 2015, 161, 185-186.	28.9	86
52	Antibody-Mediated Neutralization of Perfringolysin O for Intracellular Protein Delivery. Molecular Pharmaceutics, 2015, 12, 1992-2000.	4.6	13
53	Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3320-3325.	7.1	97
54	Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2. Cancer Cell, 2015, 27, 489-501.	16.8	158

#	Article	IF	Citations
55	Protein Engineering and Selection Using Yeast Surface Display. Methods in Molecular Biology, 2015, 1319, 3-36.	0.9	83
56	A switchable yeast display/secretion system. Protein Engineering, Design and Selection, 2015, 28, 317-325.	2.1	52
57	A Novel Bispecific CD38 Antibody Eradicates Multiple Myeloma in a Mouse Model Following Yttrium-90-DOTA Capture. Blood, 2015, 126, 118-118.	1.4	1
58	A Nonpolycationic Fully Proteinaceous Multiagent System for Potent Targeted Delivery of siRNA. Molecular Therapy - Nucleic Acids, 2014, 3, e162.	5.1	9
59	Engineered pore-forming proteins for the intracellular delivery of macromolecular therapeutics. , 2014, , .		1
60	Tumor cells are dislodged into the pulmonary vein during lobectomy. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 3224-3231.e5.	0.8	22
61	Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits. Integrative Biology (United Kingdom), 2014, 6, 388-398.	1.3	51
62	Equilibrium and dynamic design principles for binding molecules engineered for reagentless biosensors. Analytical Biochemistry, 2014, 460, 9-15.	2.4	5
63	A graphene-based physiometer array for the analysis of single biological cells. Scientific Reports, 2014, 4, 6865.	3.3	36
64	Yeast Surface Display for Antibody Isolation: Library Construction, Library Screening, and Affinity Maturation. Methods in Molecular Biology, 2014, 1131, 151-181.	0.9	65
65	Pre-Targeted Radioimmunotherapy Employing a Recombinant Bispecific Antibody Using a Murine Xenograft Model of Human Leukemia. Blood, 2014, 124, 3749-3749.	1.4	3
66	Emergent Properties of Nanosensor Arrays: Applications for Monitoring IgG Affinity Distributions, Weakly Affined Hypermannosylation, and Colony Selection for Biomanufacturing. ACS Nano, 2013, 7, 7472-7482.	14.6	45
67	Engineering Fibronectin-Based Binding Proteins by Yeast Surface Display. Methods in Enzymology, 2013, 523, 303-326.	1.0	47
68	Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Engineering, Design and Selection, 2013, 26, 663-670.	2.1	147
69	Crystal Structure of an HSA/FcRn Complex Reveals Recycling by Competitive Mimicry of HSA Ligands at a pH-Dependent Hydrophobic Interface. Structure, 2013, 21, 1966-1978.	3.3	93
70	Determination of 35 cell surface antigen levels in malignant pleural effusions identifies CD24 as a marker of disseminated tumor cells. International Journal of Cancer, 2013, 133, 2925-2933.	5.1	14
71	Synergistic Antitumor Activity from Two-Stage Delivery of Targeted Toxins and Endosome-Disrupting Nanoparticles. Biomacromolecules, 2013, 14, 1093-1102.	5.4	18
72	Localized Immunotherapy via Liposome-Anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity. Cancer Research, 2013, 73, 1547-1558.	0.9	176

#	Article	IF	Citations
73	Rapid Conformational Epitope Mapping of Anti-gp120 Antibodies with a Designed Mutant Panel Displayed on Yeast. Journal of Molecular Biology, 2013, 425, 444-456.	4.2	56
74	Targeted Cytolysins Synergistically Potentiate Cytoplasmic Delivery of Gelonin Immunotoxin. Molecular Cancer Therapeutics, 2013, 12, 1774-1782.	4.1	27
75	A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Engineering, Design and Selection, 2013, 26, 187-193.	2.1	30
76	CD8+ T-cell Responses Rapidly Select for Antigen-Negative Tumor Cells in the Prostate. Cancer Immunology Research, 2013, 1, 393-401.	3.4	0
77	Epidermal growth factor receptor downregulation by small heterodimeric binding proteins. Protein Engineering, Design and Selection, 2012, 25, 47-57.	2.1	25
78	Differential Requirement for CD70 and CD80/CD86 in Dendritic Cell-Mediated Activation of Tumor-Tolerized CD8 T Cells. Journal of Immunology, 2012, 189, 1708-1716.	0.8	32
79	Effect of Small-Moleculeâ€“Binding Affinity on Tumor Uptake In Vivo: A Systematic Study Using a Pretargeted Bispecific Antibody. Molecular Cancer Therapeutics, 2012, 11, 1365-1372.	4.1	37
80	A mechanistic compartmental model for total antibody uptake in tumors. Journal of Theoretical Biology, 2012, 314, 57-68.	1.7	85
81	Triepitopic Antibody Fusions Inhibit Cetuximab-Resistant BRAF and KRAS Mutant Tumors via EGFR Signal Repression. Journal of Molecular Biology, 2012, 422, 532-544.	4.2	30
82	Practical Theoretic Guidance for the Design of Tumor-Targeting Agents. Methods in Enzymology, 2012, 503, 255-268.	1.0	143
83	Dose Dependence of Intratumoral Perivascular Distribution of Monoclonal Antibodies. Journal of Pharmaceutical Sciences, 2012, 101, 860-867.	3.3	35
84	Convergent Potency of Internalized Gelonin Immunotoxins across Varied Cell Lines, Antigens, and Targeting Moieties. Journal of Biological Chemistry, 2011, 286, 4165-4172.	3.4	66
85	Exploiting bias in a non-immune human antibody library to predict antigenicity. Protein Engineering, Design and Selection, 2011, 24, 845-853.	2.1	1
86	A Disulfide-Free Single-Domain VL Intrabody with Blocking Activity towards Huntingtin Reveals a Novel Mode of Epitope Recognition. Journal of Molecular Biology, 2011, 414, 337-355.	4.2	33
87	Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nuclear Medicine and Biology, 2011, 38, 223-233.	0.6	55
88	Bispecific Designed Ankyrin Repeat Proteins (DARPins) Targeting Epidermal Growth Factor Receptor Inhibit A431 Cell Proliferation and Receptor Recycling. Journal of Biological Chemistry, 2011, 286, 41273-41285.	3.4	89
89	Biodistribution and Clearance of Small Molecule Hapten Chelates for Pretargeted Radioimmunotherapy. Molecular Imaging and Biology, 2011, 13, 215-221.	2.6	22
90	Integrated Mimicry of B Cell Antibody Mutagenesis Using Yeast Homologous Recombination. Molecular Biotechnology, 2011, 47, 57-69.	2.4	24

#	Article	IF	Citations
91	Surface Marker Analysis in the Evaluation of Pleural Effusions: Unique Markers Can Assist in Distinguishing Malignant From Nonmalignant Effusions. Chest, 2010, 138, 340A.	0.8	0
92	Biochemical engineering IX-interdisciplinary foundations for creating new biotechnology: II. Biotechnology and Bioengineering, 2010, 52, 183-183.	3.3	0
93	Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13252-13257.	7.1	135
94	A modular IgG-scFv bispecific antibody topology. Protein Engineering, Design and Selection, 2010, 23, 221-228.	2.1	104
95	The full amino acid repertoire is superior to serine/tyrosine for selection of high affinity immunoglobulin G binders from the fibronectin scaffold. Protein Engineering, Design and Selection, 2010, 23, 211-219.	2.1	33
96	Activation of Tolerogenic Dendritic Cells in the Tumor Draining Lymph Nodes by CD8+T Cells Engineered to Express CD40 Ligand. Journal of Immunology, 2010, 184, 3394-3400.	0.8	15
97	Cutting Edge: Delay and Reversal of T Cell Tolerance by Intratumoral Injection of Antigen-Loaded Dendritic Cells in an Autochthonous Tumor Model. Journal of Immunology, 2010, 184, 5954-5958.	0.8	18
98	Stability and CDR Composition Biases Enrich Binder Functionality Landscapes. Journal of Molecular Biology, 2010, 401, 84-96.	4.2	76
99	Yeast Display and Selections. , 2010, , 207-233.		9
100	Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5082-5087.	7.1	69
101	A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Molecular Cancer Therapeutics, 2009, 8, 2861-2871.	4.1	497
102	Soluble IL-2RA Levels in Multiple Sclerosis Subjects and the Effect of Soluble IL-2RA on Immune Responses. Journal of Immunology, 2009, 182, 1541-1547.	0.8	136
103	Directed evolution of a secretory leader for the improved expression of heterologous proteins and fullâ€length antibodies in Saccharomyces cerevisiae. Biotechnology and Bioengineering, 2009, 103, 1192-1201.	3.3	181
104	Highly avid magnetic bead capture: An efficient selection method for de novo protein engineering utilizing yeast surface display. Biotechnology Progress, 2009, 25, 774-783.	2.6	77
105	High-affinity lamprey VLRA and VLRB monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12891-12896.	7.1	104
106	Engineered Interleukin-2 Antagonists for the Inhibition of Regulatory T Cells. Journal of Immunotherapy, 2009, 32, 887-894.	2.4	38
107	A33 antigen displays persistent surface expression. Cancer Immunology, Immunotherapy, 2008, 57, 1017-1027.	4.2	61
108	Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunology, Immunotherapy, 2008, 57, 1879-1890.	4.2	80

#	Article	IF	Citations
109	Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance. Advanced Drug Delivery Reviews, 2008, 60, 1421-1434.	13.7	471
110	Monovalent, reduced-size quantum dots for imaging receptors on living cells. Nature Methods, 2008, 5, 397-399.	19.0	398
111	Picomolar Affinity Fibronectin Domains Engineered Utilizing Loop Length Diversity, Recursive Mutagenesis, and Loop Shuffling. Journal of Molecular Biology, 2008, 381, 1238-1252.	4.2	148
112	Factors determining antibody distribution in tumors. Trends in Pharmacological Sciences, 2008, 29, 57-61.	8.7	174
113	Highly<scp>l</scp>and<scp>d</scp>enantioselective variants of horseradish peroxidase discovered by an ultrahigh-throughput selection method. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17694-17699.	7.1	48
114	Quantitative Spatiotemporal Analysis of Antibody Fragment Diffusion and Endocytic Consumption in Tumor Spheroids. Cancer Research, 2008, 68, 3334-3341.	0.9	106
115	Aglycosylated immunoglobulin G₁variants productively engage activating Fc receptors. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20167-20172.	7.1	169
116	Antigen Release Kinetics in the Phagosome Are Critical to Cross-Presentation Efficiency. Journal of Immunology, 2008, 180, 1576-1583.	0.8	46
117	Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids. Molecular Cancer Therapeutics, 2008, 7, 2233-2240.	4.1	96
118	Rapid tolerization of virus-activated tumor-specific CD8 ⁺ T cells in prostate tumors of TRAMP mice. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13003-13008.	7.1	65
119	Inducing Efficient Cross-priming Using Antigen-coated Yeast Particles. Journal of Immunotherapy, 2008, 31, 607-619.	2.4	15
120	Theoretic Criteria for Antibody Penetration into Solid Tumors and Micrometastases. Journal of Nuclear Medicine, 2007, 48, 995-999.	5.0	108
121	Evolution of an Interloop Disulfide Bond in High-Affinity Antibody Mimics Based on Fibronectin Type III Domain and Selected by Yeast Surface Display: Molecular Convergence with Single-Domain Camelid and Shark Antibodies. Journal of Molecular Biology, 2007, 368, 1024-1041.	4.2	95
122	Peptide tags for enhanced cellular and protein adhesion to single-crystalline sapphire. Biotechnology and Bioengineering, 2007, 97, 1009-1020.	3.3	59
123	Selection of Horseradish Peroxidase Variants with Enhanced Enantioselectivity by Yeast Surface Display. Chemistry and Biology, 2007, 14, 1176-1185.	6.0	94
124	Computational design of antibody-affinity improvement beyond in vivo maturation. Nature Biotechnology, 2007, 25, 1171-1176.	17.5	310
125	Yeast surface display for protein engineering and characterization. Current Opinion in Structural Biology, 2007, 17, 467-473.	5.7	366
126	Protein technologies. Current Opinion in Biotechnology, 2007, 18, 293-294.	6.6	3

#	Article	IF	Citations
127	A high affinity human antibody antagonist of P-selectin mediated rolling. Biochemical and Biophysical Research Communications, 2006, 350, 508-513.	2.1	7
128	Directed evolution for improved secretion of cancerâ€“testis antigen NY-ESO-1 from yeast. Protein Expression and Purification, 2006, 48, 232-242.	1.3	33
129	A Flow Cytometric Assay for Screening Improved Heterologous Protein Secretion in Yeast. Biotechnology Progress, 2006, 22, 1200-1208.	2.6	31
130	Stochastic kinetics of intracellular huntingtin aggregate formation. Nature Chemical Biology, 2006, 2, 319-323.	8.0	65
131	Isolating and engineering human antibodies using yeast surface display. Nature Protocols, 2006, 1, 755-768.	12.0	792
132	Context-dependent mutations predominate in an engineered high-affinity single chain antibody fragment. Protein Science, 2006, 15, 324-334.	7.6	28
133	Structural Model of the mAb 806-EGFR Complex Using Computational Docking followed by Computational and Experimental Mutagenesis. Structure, 2006, 14, 401-414.	3.3	52
134	Contrasting secretory processing of simultaneously expressed heterologous proteins inSaccharomyces cerevisiae. Biotechnology and Bioengineering, 2006, 93, 896-905.	3.3	38
135	Improved mutants from directed evolution are biased to orthologous substitutions. Protein Engineering, Design and Selection, 2006, 19, 245-253.	2.1	57
136	Integrating cell-level kinetic modeling into the design of engineered protein therapeutics. Nature Biotechnology, 2005, 23, 191-194.	17.5	44
137	Directed evolution in chemical engineering. AICHE Journal, 2005, 51, 3083-3085.	3.6	0
138	Probing the interface between biomolecules and inorganic materials using yeast surface display and genetic engineering. Acta Biomaterialia, 2005, 1, 145-154.	8.3	60
139	Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast. Proteins: Structure, Function and Bioinformatics, 2005, 62, 1026-1035.	2.6	62
140	Design Criteria for Engineering Inorganic Material- Specific Peptides. Langmuir, 2005, 21, 6929-6933.	3.5	198
141	High-Affinity CD25-Binding IL-2 Mutants Potently Stimulate Persistent T Cell Growthâ€. Biochemistry, 2005, 44, 10696-10701.	2.5	63
142	Degradation of Mutated Bovine Pancreatic Trypsin Inhibitor in the Yeast Vacuole Suggests Post-endoplasmic Reticulum Protein Quality Control. Journal of Biological Chemistry, 2004, 279, 15289-15297.	3.4	64
143	Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17616-17621.	7.1	173
144	Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37ÂC. Protein Engineering, Design and Selection, 2004, 17, 293-304.	2.1	130

#	Article	IF	Citations
145	Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display. Nucleic Acids Research, 2004, 32, 36e-36.	14.5	89
146	Single-chain antibody fragment-based adsorbent for the extracorporeal removal of Î²2-microglobulin. Kidney International, 2004, 65, 310-322.	5.2	15
147	Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments. Journal of Immunological Methods, 2004, 287, 147-158.	1.4	90
148	Identification of the Epitope for the Epidermal Growth Factor Receptor-specific Monoclonal Antibody 806 Reveals That It Preferentially Recognizes an Untethered Form of the Receptor. Journal of Biological Chemistry, 2004, 279, 30375-30384.	3.4	122
149	Engineering Antibody Affinity by Yeast Surface Display. Methods in Enzymology, 2004, 388, 348-358.	1.0	121
150	Fine Epitope Mapping of anti-Epidermal Growth Factor Receptor Antibodies Through Random Mutagenesis and Yeast Surface Display. Journal of Molecular Biology, 2004, 342, 539-550.	4.2	129
151	Development of a Human Light Chain Variable Domain (VL) Intracellular Antibody Specific for the Amino Terminus of Huntingtin via Yeast Surface Display. Journal of Molecular Biology, 2004, 342, 901-912.	4.2	93
152	Interleukin 2 (IL-2) Variants Engineered for Increased IL-2 Receptor Î±-Subunit Affinity Exhibit Increased Potency Arising from a Cell Surface Ligand Reservoir Effect. Molecular Pharmacology, 2004, 66, 864-869.	2.3	42
153	Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nature Biotechnology, 2003, 21, 163-170.	17.5	462
154	Rapid Method for Measuring ScFv Thermal Stability by Yeast Surface Display. Biotechnology Progress, 2003, 19, 631-638.	2.6	54
155	Rolling Adhesion Kinematics of Yeast Engineered To Express Selectins. Biotechnology Progress, 2003, 19, 1033-1037.	2.6	13
156	Interleukin-2 mutants with enhanced Â-receptor subunit binding affinity. Protein Engineering, Design and Selection, 2003, 16, 1081-1087.	2.1	58
157	Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Research, 2003, 63, 1288-96.	0.9	140
158	Jay Bailey as mentor?The students' perspective. Biotechnology and Bioengineering, 2002, 79, 484-489.	3.3	1
159	Quantitative Screening of Yeast Surface-Displayed Polypeptide Libraries by Magnetic Bead Capture. Biotechnology Progress, 2002, 18, 212-220.	2.6	73
160	Protein engineering by cell-surface display. Current Opinion in Biotechnology, 2001, 12, 395-399.	6.6	186
161	Glutathione excretion in response to heterologous protein secretion insaccharomyces cerevisiae. , 2000, 68, 389-395.		14
162	The single cell as a microplate well. Nature Biotechnology, 2000, 18, 1039-1040.	17.5	6

#	Article	IF	Citations
163	Fine Affinity Discrimination by Yeast Surface Display and Flow Cytometry. Biotechnology Progress, 2000, 16, 31-37.	2.6	140
164	[25] Yeast surface display for directed evolution of protein expression, affinity, and stability. Methods in Enzymology, 2000, 328, 430-444.	1.0	280
165	Glutathione excretion in response to heterologous protein secretion in saccharomyces cerevisiae. Biotechnology and Bioengineering, 2000, 68, 389.	3.3	1
166	A small-molecule catalyst of protein folding in vitro and in vivo. Chemistry and Biology, 1999, 6, 871-879.	6.0	79
167	Biosynthetic polypeptide libraries. Current Opinion in Biotechnology, 1999, 10, 117-122.	6.6	34
168	Phage on display. Trends in Biotechnology, 1999, 17, 423-424.	9.3	28
169	Expression of the 180-kD Ribosome Receptor Induces Membrane Proliferation and Increased Secretory Activity in Yeast. Journal of Cell Biology, 1999, 146, 273-284.	5.2	49
170	Optimal Screening of Surface-Displayed Polypeptide Libraries. Biotechnology Progress, 1998, 14, 55-62.	2.6	127
171	Increasing the secretory capacity of Saccharomyces cerevisiae for production of single-chain antibody fragments. Nature Biotechnology, 1998, 16, 773-777.	17.5	244
172	Leader peptide efficiency correlates with signal recognition particle dependence inSaccharomyces cerevisiae. , 1998, 59, 286-293.		17
173	Thermodynamic characterization of affinity maturation: the D1.3 antibody and a higher-affinity mutant. , 1998, 11, 10-13.		14
174	Secretion Efficiency inSaccharomyces cerevisiaeof Bovine Pancreatic Trypsin Inhibitor Mutants Lacking Disulfide Bonds Is Correlated with Thermodynamic Stabilityâ€. Biochemistry, 1998, 37, 1264-1273.	2.5	78
175	Protein Folding Stability Can Determine the Efficiency of Escape from Endoplasmic Reticulum Quality Control. Journal of Biological Chemistry, 1998, 273, 19453-19458.	3.4	110
176	Yeast surface display for screening combinatorial polypeptide libraries. Nature Biotechnology, 1997, 15, 553-557.	17.5	1,579
177	Expression Level Tuning for Optimal Heterologous Protein Secretion in Saccharomyces cerevisiae. Biotechnology Progress, 1997, 13, 117-122.	2.6	46
178	Biochemical engineering IXâ€"interdisciplinary foundations for creating new biotechnology: I. Biotechnology and Bioengineering, 1996, 52, 1-2.	3.3	4
179	An Integrating Vector for Tunable, High Copy, Stable Integration into the Dispersed Ty Î´ Sites of Saccharomyces cerevisiae. Biotechnology Progress, 1996, 12, 16-21.	2.6	102
180	Reduction of BiP Levels Decreases Heterologous Protein Secretion in Saccharomyces cerevisiae. Journal of Biological Chemistry, 1996, 271, 10017-10022.	3.4	82

#	Article	IF	Citations
181	Constitutive overexpression of secreted heterologous proteins decreases extractable heavy chain binding protein and protein disulfide isomerase levels in Saccharomyces cerevisiae. Biotechnology Progress, 1995, 11, 171-177.	2.6	44
182	Disulfide bond formation and eukaryotic secretory productivity. Current Opinion in Biotechnology, 1995, 6, 203-208.	6.6	38
183	Protein Disulfide Isomerase Overexpression Increases Secretion of Foreign Proteins in Saccharomyces cerevisiae. Bio/technology, 1994, 12, 381-384.	1.5	185
184	Stochastic simulation of 2.mu. multicopy plasmid amplification in yeast. Biotechnology Progress, 1993, 9, 160-165.	2.6	2
185	Role of the Protein-Folding Chaperone BiP in Secretion of Foreign Proteins in Eukaryotic Cells. ACS Symposium Series, 1993, , 121-132.	0.5	5
186	Mathematical modeling of a single-cell enzyme assay. Biotechnology and Bioengineering, 1990, 35, 525-532.	3.3	9
187	Propagation of an amplifiable recombinant plasmid inSaccharomyces cerevisiae: flow cytometry studies and segregated modeling. Biotechnology and Bioengineering, 1990, 35, 565-577.	3.3	21
188	A single-cell assay of Î²-galactosidase activity inSaccharomyces cerevisiae. Cytometry, 1988, 9, 394-404.	1.8	50
189	A mathematical model of recombinational amplification of the 2Î¼ plasmid in the yeast Saccharomyces cerevisiae. Journal of Theoretical Biology, 1988, 130, 481-492.	1.7	5
190	Directed Evolution of Binding Proteins by Cell Surface Display: Analysis of the Screening Process. , 0, , 111-126.		1
191	Identification of Highly Cross-Reactive Mimotopes for a Public T Cell Response in Murine Melanoma. Frontiers in Immunology, 0, 13, .	4.8	5